GMAB News and Press, Genmab A/S From 05/01/24

2024-05-01 11:22:41 ET Major earnings expected before the bell on Thursday include: ConocoPhillips ( COP ) Iron Mountain ( IRM ) Moderna ( MRNA ) Organon ( OGN ) Shell ( SHEL ) Read the full article on Seeking Alpha For further details...

2024-05-01 10:27:47 ET Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contrib...

2024-04-30 06:26:54 ET Pfizer ( NYSE: PFE ) and Danish drugmaker Genmab ( GMAB ) announced Monday that the U.S. FDA accepted a supplemental Biologics License Application granting full approval for their cervical cancer therapy, Tivdak (tisotumab vedotin-tftv).... Read ...

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating ...

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data Genmab A/S (...

2024-04-29 15:08:53 ET Summary AbbVie Inc.'s shares dropped last week due to concerns about the erosion of Humira and despite the company beating revenue and EPS expectations. Humira's global sales fell 36% YoY, but AbbVie's other growth products performed well, leading to overall...

2024-04-29 08:51:30 ET Summary Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics...

2024-04-16 11:20:38 ET Summary Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to advance ProfoundBio's lead candidate, Rina-S, to registrat...

2024-04-16 07:20:23 ET Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson ( NYSE: JNJ ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts.... Read the full a...

2024-04-08 15:15:00 ET Summary Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion. The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months. The deal comes...